While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...
Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share ...
KalVista reports early EKTERLY sales momentum, rising prescriber adoption and global regulatory approvals following the drug's 2025 launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback